Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024)
Maze Therapeutics recorded quarterly Preferred Stock Liabilities of $508.1 million in Q4 2024, up 32.35% quarter-over-quarter from $383.9 million in Q3 2024.
Maze Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $508.1 million for Q4 2024.
- In Q4 2024, Preferred Stock Liabilities changed N/A year-over-year to $508.1 million; the TTM figure through Dec 2024 stood at $508.1 million (changed N/A YoY), while the FY2024 annual figure was $508.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $508.1 million for Q4 2024 at Maze Therapeutics, up from $383.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $508.1 million in Q4 2024 to a low of $383.9 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 508.09 Mn |
| Sep 30, 2024 | 383.90 Mn |
| Jun 30, 2024 | 383.90 Mn |
| Mar 31, 2024 | 383.90 Mn |